Author: sHq_LoGiNz

NEWARK, Calif., April 1, 2026 /PRNewswire/ — Lucid Group, Inc. (NASDAQ: LCID), maker of the world’s most advanced software-defined vehicles and technologies, today announced that the Lucid Gravity has been named 2026 World Luxury Car of the Year by the esteemed World Car Awards program. In an awards category open to electric, hybrid, and internal-combustion vehicles, Lucid’s all-electric SUV was recognized by a global jury of more than 100 acclaimed automotive journalists from around the globe. Lucid is now 2-for-2 in this award category, with the Lucid Air sedan named World Luxury Car of the Year in 2023. Now in its 22^nd year, the World Car Awards aim to recognize, reward and inspire automotive excellence, leadership and innovation in a rapidly changing automotive industry on a global scale.

“This recognition reflects the strength of Lucid’s product vision and the exceptional execution of our team,” said Marc Winterhoff, Interim CEO of Lucid. “Lucid Gravity brings together the space and versatility of a full-size SUV with sports‑car‑like driving dynamics and a refined luxury experience, enabled by our proprietary technology and engineering. Together, these qualities set a new benchmark for what a world‑class luxury SUV can be.”

On and off the road, Gravity’s exceptional performance starts with a brand-new platform developed from the ground up as a sporty SUV. Featuring two motors, all-wheel drive, and a standard adjustable air suspension, it’s an SUV that delivers a smooth, comfortable ride for passengers on any road, even when the pavement ends and the trail begins. The Lucid Gravity’s available rear-axle steering system enhances high-speed driving dynamics for exceptional handling on winding roads and makes day-to-day driving easier than ever by shortening the space needed for the vehicle to maneuver through tight city streets and crowded parking lots.

Lucid Gravity redefines the SUV category by delivering full‑size SUV practicality within a mid‑size footprint, with a spacious and accommodating interior comfortably seating up to seven adults while offering uncompromising space, efficiency, performance, and usability. The sliding second row seats combine with available integrated convenience tables for an elevated back-seat experience. Remarkable legroom is carried through to the third row, enabling a comfortable seven-passenger configuration, making it the ideal vehicle for every adventure.

Powering it all is Lucid Gravity’s high‑efficiency, miniaturized powertrain and ultra‑fast charging. The result is up to 450 miles of EPA-estimated driving range and DC fast-charging that can add 200 miles of range in less than 11 minutes, ensuring the easiest and fastest possible charging experience at over 32,500 DC fast charging stations in North America.

The Lucid Gravity will be featured at the 2026 New York International Auto Show from April 3-12. Not only can show attendees get a close look at its class-leading space and packaging, luxury appointments, and user experience first-hand, they can also experience Lucid Gravity’s performance in the show’s EV test track.

Lucid Gravity is available to order at Lucidmotors.com/gravity.

About Lucid Group 
Lucid Group, Inc. (NASDAQ: LCID) is a technology company creating exceptional mobility experiences through innovation to drive the world forward. Built on Lucid’s proprietary technology and software defined vehicle architectures, the company’s lineup of award-winning vehicles brings Lucid’s “Compromise Nothing™” approach to premium segments of the global automotive market. Lucid designs and engineers its products in-house and assembles them at its vertically integrated facilities in Arizona and Saudi Arabia, enabling continuous innovation across vehicles, software, and advanced driver assistance and autonomy-ready capabilities.

Media Contact
media@lucidmotors.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-gravity-suv-recognized-as-the-2026-world-luxury-car-of-the-year-302731892.html

SOURCE Lucid Group

ST. LOUIS, April 1, 2026 /PRNewswire/ — Nestlé Purina PetCare Company is helping support pets and people in rural Western Alaska by donating 45,000 pounds of Purina dog food to communities still recovering from Typhoon Halong.

The storm struck Alaska in October 2025 and brought hurricane-force winds and catastrophic flooding, heavily impacting nearly 50 rural and native communities. In many of these regions, dogs play a critical role in daily life, providing not only companionship, but transportation and safety—making access to nutrient dense pet food essential.

Purina learned about the ongoing need in Western Alaska from Dr. Arleigh Reynolds, DVM, PhD, D.A.C.V.N., a retired Purina veterinarian, scientist and current medical advisor working with Alaska Native Rural Veterinary, Inc., an organization dedicated to improving animal health in remote Alaska communities. “Purina has a long and dedicated history of helping pets and their owners when they need it most. Dogs play a huge role in the emotional and mental health resilience and recovery responses to traumatic events like this typhoon. We are so very grateful for this lifesaving support,” said Dr Reynolds.

“Dogs are essential to daily life in many of Alaska’s rural communities, and access to food can be a real challenge long after a disaster makes headlines,” said Angie Fitch, Executive Director & Co-Founder of Alaska Native Rural Veterinary, Inc. “Purina’s generosity—and the commitment of so many transportation partners—will make a meaningful difference for dog owners in communities that are still working to recover months after Typhoon Halong. This support helps ensure families can continue caring for the dogs they love and depend on.”

Moved by the scale and persistent challenges facing pet owners months after the storm, Purina mobilized a plan to send help. In addition to producing and donating a full truckload of dog food, Purina partnered with Greater Good Charities to coordinate the logistics required to transport the donation from the Purina factory in Eden, North Carolina, to a port in Tacoma, Washington. An emergency grant from the Purina Foundation covered the more than $6,000 in shipping costs, ensuring the food could make the long journey from the East Coast to the Pacific Northwest and continue on to Western Alaska.

Alaska Native Rural Veterinary, Inc. is now working with a network of transportation partners to deliver the donated dog food directly to pet owners in remote communities. These partners include TOTE Maritime, Carlile Transportation, Alaska Air Transit, Resolve Aviation, Aleutian Airways, NAC Alaska, Ryan Air, Warbelows Air Ventures and Everts Air —each playing a critical role in reaching communities that are often accessible only by air or sea.

“Recovery doesn’t end when the storm passes, especially in rural and remote communities,” said Kim Beardslee, Director of Community Affairs at Purina. “We’re proud to work alongside trusted partners to help ensure pets and people have the resources they need as these communities continue to rebuild.”

Supporting communities in times of crisis is a core part of Purina’s commitment to keeping pets and people together. In the wake of a natural disaster, Purina works closely with Greater Good Charities to provide timely assistance—combining pet food donations, emergency funding, and operational expertise to help pet owners care for their animals during recovery. From immediate response to long‑term rebuilding, Purina focuses on meeting critical needs where access to resources may be limited, ensuring pets continue to receive the care they deserve as communities heal.

About Purina
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations.

Purina manufactures some of the world’s most trusted and popular pet care products, including Dog Chow, Purina ONE, Pro Plan, Friskies and Tidy Cats. Our more than 11,000 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 46 million dogs and 68 million cats every year. Nearly 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition.

Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive.

Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.

View original content to download multimedia:https://www.prnewswire.com/news-releases/purina-donates-45-000-pounds-of-dog-food-to-support-rural-communities-in-western-alaska-recovering-from-typhoon-halong-302731857.html

SOURCE Purina

4th-generation executive director is proud to carry on the legacy of great-grandmother Bessie Tartt Wilson who founded the school on then-Holborn Terrace

BOSTON, April 1, 2026 /PRNewswire/ — TARTTs Day Care Centers (“TARTTs”), a landmark institution in the Boston early childhood education landscape is proud to announce its 80th anniversary this year.

Founded in May of 1946 by Bessie Tartt Wilson, the historic milestone follows close behind the one-year anniversary of when TARTTs became part of the Cadence Education family. The transfer of ownership allowed TARTTs to maintain its family-centered mission while gaining the support of a national educational network.

“We are privileged to honor the mission that Bessie Tartt Wilson started eight decades ago, while ensuring that TARTTs has the modern resources to remain at the forefront of early childhood education in Boston, a city with such rich commitment to education,” CEO of Cadence Education Leigh-Ellen Louie said. 

Nida Wright Adjetey, former vice president and current Executive Director of TARTTs, said she was proud to remain on board to oversee the three locations she and her family built and maintained.

“Our long history is defined by resilience and a commitment to quality,” Wright Adjetey said. “From our roots in Roxbury/Dorchester to our expansion in the South End, we have always prioritized the social and academic development of the ‘total child.'”

The TARTTs story began when Bessie Tartt Wilson, then a 23-year-old recent nursing school graduate from Alabama, relocated to Boston to find work in her field. Everything changed due to lingering after-effects following a battle with polio that would have made it challenging to keep up with the physical demands of nursing. 

Wilson’s tenacity led her to pivot to early childhood education by providing care in her own home on a street that today we call Kavanaugh Way—formerly known as Holborn Terrace. The decision created a new life trajectory that would impact not only her family, but countless families in Boston—for generations to come.

In fact, following Wilson’s death in 1999, under the subsequent leadership of Bessie’s daughter, Mary L. Reed, and grandchildren, Ken Reed and Wanda Geer, the home-based business expanded into a commercial property. Until late 2019, TARTTs Day Care Center II occupied suites within the municipal building owned by the City of Boston at 1010 Massachusetts Ave., after purchasing and expanding the YMCA daycare operating at that site.

TARTTs thrived for almost 20 years at that location, which today continues to be a hub for Boston municipal services. And TARTTs has long since put down new roots elsewhere.

As the business outgrew its domestic roots, TARTTs successfully began transitioning into its current footprint in Boston’s vibrant South End and SoWa districts. All three locations are within walking distance of each other making it easy for parents and staff to navigate needs based on age-based services or availability within each location.

“We also have roots in the South End, where we were raised and my mom and grandmother still reside,”  Wright Adjetey said. “So, expanding to the South End was a profitable and strategic business move, but it was also returning home.”

Today, under the Cadence Education umbrella, the school operates three locations:

• TARTTs South End (Harrison Ave.)
• TARTTs SOWA (Harrison Ave.)
• TARTTs at The Factory (Wareham St.)

“Celebrating 80 years is a testament to the enduring vision of my great-grandmother and the generations of families who have trusted us with their children’s futures,” said Wright Adjetey. “Our role is also to support the teachers who are the heart of TARTTs and to ensure our legacy of continuity of care remains the standard for Boston families.”

About TARTTs Day Care Centers
Founded in 1946 by Bessie Tartt Wilson in Boston, TARTTs Day Care Centers provides comprehensive early childhood education focused on social, physical, and academic development. Operating three locations in Boston’s South End and SoWa areas, TARTTs joined the Cadence Education family of schools in December 2024.

About Cadence Education
Cadence Education is one of the premier early childhood educators in the United States, operating more than 320 private preschools and elementary schools across the country. With over 30 years of experience, Cadence Education is dedicated to providing personalized excellence in childcare and early education. For more information, visit www.cadence-education.com.

Media Contacts:
Media Relations
Media@Cadence-Education.com

Timeline sidebar, historic and current photos are available upon request.

View original content to download multimedia:https://www.prnewswire.com/news-releases/a-boston-legacy-tartts-day-care-centers-celebrate-80-years-of-nurturing-the-total-child-302731694.html

SOURCE TARTTs

MENLO PARK, Calif., April 1, 2026 /PRNewswire/ — Global talent solutions and business consulting firm Robert Half (NYSE: RHI) has again been selected as one of Fortune’s 100 Best Companies to Work For^®. Robert Half’s consulting subsidiary, Protiviti, is also included on the highly competitive list.

Fortune 100 Best Companies to Work For recognizes top organizations with innovative programs that reflect a genuine commitment to meeting employee needs inside and outside the workplace, as validated by employee feedback. Great Place To Work^® analyzed anonymous survey responses from more than 1.3 million professionals from Great Place To Work Certified^™ companies with at least 1,000 employees in the U.S. Organizations are assessed on their efforts to create supportive, high-performance work experiences for every person in the organization.

“This recognition reflects our ongoing commitment to fostering a people-first approach,” said M. Keith Waddell, president and chief executive officer of Robert Half. “Our core values—integrity, inclusion, innovation and commitment to success—are embedded in our organizational culture, empowering employees to reach their full potential both personally and professionally.”

The survey also examined how responses varied across demographic groups and roles, providing insight into the consistency of the employee experience. Key indicators include accessibility to leaders, connection with colleagues and pride in work.

“Our focus remains on our people, with a commitment to supporting their growth and providing an environment where they can thrive and perform at their best,” said JoLynn Conway-James, senior executive director and chief administrative officer at Robert Half. “We take pride in our workplace culture, where employees feel valued, heard and supported.”

Robert Half is committed to supporting employees at every stage of their career and in the moments that matter most to them. In addition to ongoing recognition and mentoring programs, the company has invested in tools and technologies to improve the employee experience, including:

• Personalized learning paths: The organization customizes professional development and training by role and department, allowing employees to focus on the skills that support their growth and career advancement.
• Enhanced onboarding experience: By leveraging technology to simplify workflows, Robert Half offers an interactive and comprehensive onboarding experience for new employees and hiring managers, reducing manual effort and improving consistency across the organization.
• Self-service options: To help employees get faster answers to benefits questions, financial well-being needs (including retirement savings) and company policies, Robert Half offers a range of self-service tools, complemented by high-touch, individualized support.

FAQs
How does Robert Half support its employees?
Robert Half’s employee commitment focuses on supporting its people by prioritizing well-being, investing in career growth, fostering connection and empowering them to make a meaningful impact.

What innovative programs is Robert Half pursuing to build a world-class employee experience?
Through customized development opportunities and leadership pathways, a new performance review platform and continuous listening strategy, and emerging technologies that combine human judgment with AI-driven efficiency, employees are empowered to work smarter and stay future-ready.

Does Robert Half help clients build strong workplace cultures?
Robert Half helps clients build strong workplace cultures by delivering forward-looking talent solutions and consulting services aligned with their organizational goals.

About Robert Half
Robert Half is the world’s first and largest specialized talent solutions and business consulting firm, connecting highly skilled job seekers with rewarding opportunities at great companies. We offer contract talent and permanent placement solutions in the fields of finance and accounting, technology, marketing and creative, legal, and administrative and customer support, and we also provide executive search services. Robert Half is the parent company of Protiviti^®, a global consulting firm that delivers internal audit, risk, business and technology consulting solutions. In the past 12 months, Robert Half, including Protiviti, has been named one of the Fortune^® Most Admired Companies™ and one of Newsweek’s Most Charitable Companies. Explore talent solutions, research and insights at RobertHalf.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/robert-half-recognized-by-fortune-as-one-of-the-100-best-companies-to-work-for-302731529.html

SOURCE Robert Half

Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial¹

Foundayo, Lilly’s second FDA-approved obesity medicine, will be available via LillyDirect^® with free home delivery, starting at $25 per month with commercial coverage and $149 for self-pay

INDIANAPOLIS, April 1, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo will be available via LillyDirect^®, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through U.S. retail pharmacies and telehealth providers.

“People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment,” said Deborah Horn, DO, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston. “With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials – addressing both the clinical realities of obesity and the practical challenges patients face every day.”

Supported by the rigorous ATTAIN clinical trial program, Foundayo was proven to help people lose weight and keep it off. In the ATTAIN-1 trial, individuals taking the highest dose of Foundayo and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo.¹ Participants taking Foundayo, regardless of trial completion, lost an average of 25 pounds (11.1%), compared to 5.3 pounds (2.1%) with placebo.² In the ATTAIN program, Foundayo also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses.

“Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn’t serious enough for treatment. We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications,” said David A. Ricks, chair and CEO of Eli Lilly and Company. “As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world.”

Lilly is committed to making Foundayo accessible and affordable. Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card.³ Individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose. Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning as soon as July 1, 2026.

Use of Foundayo with other GLP-1 receptor agonist medicines is not recommended. It is not known whether Foundayo is safe and effective for use in children. Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath. If you have any of these symptoms, tell your health care provider. The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Please see Indication and Safety Summary with Warning below and full Prescribing Information and Medication Guide.

“There is no single path that works for everyone living with overweight or obesity,” said Joe Nadglowski, president and CEO of the Obesity Action Coalition. “New treatment options expand choice and help more people find care that fits their lives, their goals and where they are in their journey – whether they’re just starting to explore treatment or looking for a different long-term approach.”

Lilly has submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each country shortly after approval.

For more information about Foundayo, please visit www.foundayo.lilly.com. 

About Foundayo (orforglipron)⁴
Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.⁵ Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About ATTAIN-1 and ATTAIN-2 clinical trial program
The ATTAIN Phase 3 global clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight across two global registration trials.

ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes. The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in body weight reduction from baseline after 72 weeks.

ATTAIN-2 (NCT05872620) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes. The trial randomized over 1,600 participants across the U.S., Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in mean body weight change from baseline at 72 weeks.

INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo™ (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

• Foundayo should not be used with other GLP-1 receptor agonist medicines.
• It is not known if Foundayo is safe and effective for use in children.

Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

• Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
• Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

• Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works.
• Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
• If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo.
• Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.

Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

• Take Foundayo exactly as your healthcare provider tells you to.
• Use Foundayo with a reduced-calorie diet and increased physical activity.
• Take Foundayo by mouth 1 time each day, with or without food.
• Swallow tablets whole. Do not break, crush, or chew the tablet.
• If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day.
• Do not take more than 1 tablet per day.
• If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment.
• If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

Foundayo^™ is a trademark of Eli Lilly and Company.

Endnotes and References 

1. The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) for 72 weeks without initiating prohibited weight management treatments.⁴
2. The treatment-regimen estimand represents the estimated average treatment effect regardless of adherence to study intervention or initiation of prohibited weight management treatments.⁴
3. Terms and conditions apply. Learn more at foundayo.lilly.com.
4. Foundayo. Prescribing Information. Lilly USA, LLC.
5. Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832. https://doi.org/10.1007/s13300-024-01554-1. Epub 2024 Feb 24. PMID: 38402332; PMCID: PMC10951152.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo as a treatment for adults with obesity or some adults with overweight who also have weight-related medical problems and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study results to date, that Foundayo will receive additional regulatory approvals, or that Foundayo will be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Trademarks and Trade Names 
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ^® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

CMAT-04552 04/2026 ©Lilly USA, LLC 2026. All rights reserved.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html

SOURCE Eli Lilly and Company

Novel Transdermal Curcumin Formulation Demonstrates Pain Reduction and Improved Quality of Life in Phase 1b Clinical Trial

Study published in Frontiers in Pain Research reports significant reduction in knee pain with topical curcumin formulation

SUMMIT, N.J., April 1, 2026 /PRNewswire/ — Vascarta Inc. today announced the publication of results from a randomized, double-blind, placebo-controlled clinical trial evaluating VAS-101, the company’s investigational topical/transdermal curcumin gel, for the treatment of knee pain associated with osteoarthritis. The study appears in the peer-reviewed journal Frontiers in Pain Research. Frontiers | The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study

The clinical trial demonstrated that participants using VAS-101 experienced statistically significant reductions in knee pain compared with placebo, along with a favorable safety and tolerability profile.

Dr. Adrian Lopresti, Managing Director of Clinical Trials Australia and principal investigator, stated, “The results of this study demonstrate that, in people with knee osteoarthritis, the topical application of VAS-101 reduced knee pain within 28 days, with clinically meaningful improvements occurring in approximately 40% of participants. VAS-101 may represent a promising option for individuals experiencing knee osteoarthritis.”

Study Design
The randomized, double-blind, placebo-controlled trial enrolled 60 adults aged 45–75 with knee osteoarthritis. Participants applied either 0.1 mL VAS-101 or 0.1 mL placebo gel to the affected knee every other day for 28 days.

Researchers assessed outcomes using several validated measures, including:

• KOOS pain subscale (primary endpoint)
• Daily pain ratings
• Performance-based physical function tests
• Use of rescue oral pain medication

Key Findings
Results from the study showed that VAS-101 produced meaningful improvements in pain outcomes compared with placebo:

• Significant improvement in KOOS pain score (β: 5.12; 95% CI: 0.47–9.77; p = 0.041)
• Significant reduction in daily pain ratings (p = 0.005)
• 39.3% of participants using VAS-101 reported feeling “much improved” or “very much improved,” compared with 13.3% in the placebo group (p = 0.019)
• 32.1% of participants achieved a Minimal Clinically Important Difference in symptoms, compared with 13.3% with placebo

VAS-101 was well tolerated, with no significant adverse reactions reported. Temporary skin staining, a known characteristic of topical curcumin, was observed but resolved within two to three days after discontinuation.

Implications
The study suggests that topical delivery of curcumin may offer a promising non-oral therapeutic approach to managing osteoarthritis-related knee pain, potentially addressing limitations associated with oral formulations.

While further research with larger patient populations and longer treatment durations is needed, these findings highlight the potential role of VAS-101 in managing osteoarthritis pain,” said Joel Friedman, M.D., Ph.D., inventor of Vascarta’s patented transdermal drug delivery technology, Professor Emeritus at Albert Einstein College of Medicine, and Chief Scientific Officer.

Chairman and CEO Richard Prince, Ph.D. added: “These data indicate the potential of VAS-101 to become the standard of care in osteoarthritis. We intend to accelerate our efforts in the development of VAS-101 for osteoarthritis with the anticipated filing of an Investigational New Drug Application to the United States Food & Drug Administration later this year.” 

About Knee Osteoarthritis
Knee osteoarthritis is a degenerative joint condition affecting millions of adults worldwide. It is characterized by chronic pain, stiffness, reduced mobility, and progressive deterioration of joint cartilage.

About VAS-101
VAS-101 is an investigational topical curcumin formulation developed and patented by Vascarta. It is designed to deliver curcumin through the skin directly into affected joints, potentially providing localized and enhanced systemic anti-inflammatory and analgesic effects.

About Vascarta
Vascarta Inc. is a clinical-stage pharmaceutical company focused on developing therapies to address chronic pain and inflammation. The company’s proprietary drug delivery platform supports a growing pipeline of therapies targeting inflammatory diseases and cancer.

The company’s lead candidate, Vasceptor® (VAS-101), is a topically applied transdermal formulation utilizing curcumin as its active pharmaceutical ingredient. By bypassing the gastrointestinal tract and first-pass liver metabolism, the transdermal route may enhance curcumin delivery into systemic circulation compared with oral formulations.

Contacts for further information:
Dr. Richard Prince
Chairman, CEO & President
rprince@vascarta.com

Mr. David Hymson
Communications
dhymson@vascarta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vascarta-announces-positive-clinical-trial-results-for-topicaltransdermal-curcumin-gel-vas-101-in-knee-osteoarthritis-302731447.html

SOURCE Vascarta Inc